PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Latest Additions

Latest Additions

Records returned : 169 (on 24 Apr 2024 at 01:12:52).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
01.03.05
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSCH
SASH
SABP
Important
Preferred
1st line option in children who are able to swallow capsules. Most capsules can also be opened and mixed with water or fruit juice (licensed).
07.04.01
Green
Formulations :
  • Immediate release tablets
Primary Care
ASPH
RSCH
SASH
SABP
Preferred
Green
Formulations :
  • Modified release capsules
Primary Care
ASPH
RSCH
SASH
SABP
Preferred
07.04.02
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
Preferred
1st line unless contra-indicated
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
04.07.04
04.08.01
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
04.07.03
04.07.04
Green
Formulations :
  • Oral solution
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
04.07.03
04.07.04
Green
Formulations :
  • Oral solution
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Preferred
04.07.02
Green
Formulations :
  • Modified release capsules
  • Modified release tablets
  • Oral solution
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
Important
Prescribe modified-release preparations by brand - refer to local guidelines for preferred brands
04.06.00
Green
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
SA
Un
04.07.03
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
Un
Important
Licensed only for diabetic peripheral neuropathic pain but also recommended as per NICE CG173 (off- label indication) as a treatment option in neuropathic pain.
04.07.03
04.07.04
04.08.01
Green
Formulations :
  • Capsules
  • Oral solution
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
First line gabapentinoid.
01.03.05
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSCH
SASH
SABP
Important
Preferred
1st line for patients with no swallowing difficulties. 2nd line for adults with swallowing difficulties / feeding tubes - capsules can be opened. Click on drug name for details
01.03.05
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSCH
SASH
SABP
Important
Preferred
1st line for patients with no swallowing difficulties.
03.04.03
Green
Formulations :
  • Auto-injector
Primary Care
ASPH
RSCH
SASH
SABP
Important
Prescribe by brand. Injection technique is device-specific
10.02.02
Green
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
U
Green
Formulations :
  • Powder
Primary Care
ASPH
RSCH
SASH
SABP
10.03.02
Green
Formulations :
  • Cream
Primary Care
ASPH
RSCH
SASH
SABP
Important
0.025% cream (Zacin brand) is licensed for this indication. (0.075% Axsain cream is NOT licensed for osteoarthritis)
06.04.02
Green
Formulations :
  • Gel
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
Un
Important
Prescribe generically as "Testosterone 2% transdermal gel 60g"
06.01.02
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.
09.06.04
Green
Formulations :
  • Capsules
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
1,000iu tablets 50,000iu capsules
Green
Formulations :
  • Powder
Primary Care
ASPH
RSCH
SASH
SABP
Green
Formulations :
  • Immediate release tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
Preferred
Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
Un
Important
Off-label use
06.01.01
Green
Formulations :
  • Injection
Primary Care
ASPH
RSCH
SASH
SABP
10.03.02
Green (see narrative)
Formulations :
  • Cream
Primary Care
ASPH
RSCH
SASH
SABP
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
0.075% cream (Axsain brand) is licensed for this indication
04.07.03
04.07.04
04.08.01
Green (see narrative)
Formulations :
  • Oral solution
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
Green (see narrative)
Formulations :
  • Capsules
  • Soluble tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
Important
NICE CG 173 Consider tramadol only if acute rescue therapy is needed. Prescribe a short course (2-4 weeks on an acute script) and review at least every 3 months.
04.07.02
Green (see narrative)
Formulations :
  • Modified release capsules
  • Modified release tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
Important
NICE CG 173 Consider tramadol only if acute rescue therapy is needed. Prescribe a short course (2-4 weeks on an acute script) and review at least every 3 months.
MR preparations to be prescribed by brand. Marol MR tablets are the locally preferred brand for primary care.
09.06.04
Green (see narrative)
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
4,000iu tablets reserved for patients unable to comply with weekly dosing
09.06.04
Green (see narrative)
Formulations :
  • Oral solution
Primary Care
ASPH
RSCH
SASH
SABP
Important
50,000iu/ml oral solution in ampoules - reserved for patients unable to swallow tablets / capsules
09.06.04
Green (see narrative)
Formulations :
  • Oral drops
Primary Care
ASPH
RSCH
SASH
SABP
Important
10,000iu/ml oral drops sugar free - reserved for patients unable to swallow tablets / capsules
06.06.02
Green (see narrative)
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSCH
SASH
SABP
Important
Patients with a CKD of 4 or 5 and patients with a T-score of < -4.5 to remain under specialist care.
Green (see narrative)
Formulations :
  • Ointment
Primary Care
ASPH
RSCH
SASH
SABP
Important
Preferred
0.4% ointment is the 1st-line treatment option in adults
01.03.05
Green (see narrative)
Formulations :
  • Oro-dispersible
Primary Care
ASPH
RSCH
SASH
SABP
Important
1st line in adults with swallowing difficulties. 1st line for patients with enteral feeding tubes.
01.03.05
Green (see narrative)
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
Green (see narrative)
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
01.03.05
Green (see narrative)
Formulations :
  • Dispersible tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
Mezzopram is the preferred brand - smaller granule size. Omeprazole MUPS is an alternative. Disperse in water then mix with juice, apple sauce or yoghurt
04.07.03
04.07.04
04.08.01
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
SA
Important
Gabapentin is preferred due to lower potential for misuse. Pregabalin capsules more cost effective than tablets
04.07.03
Green (see narrative)
Formulations :
  • Medicated plaster
Primary Care
ASPH
RSCH
SASH
SABP
Important
Post herpetic neuralgia only. Acute Trusts are restricted to Pain Team initiation only
01.03.05
Green (see narrative)
Formulations :
  • Dispersible tablets
Primary Care
ASPH
RSCH
SASH
SABP
04.07.02
Green (see narrative)
Formulations :
  • Capsules
  • Modified release tablets
  • Oral solution
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
Important
2nd-line, for patients unable to tolerate / poor response to morphine. Modified-release preparations to be prescribed by brand
Green (see narrative)
Formulations :
  • Capsules
  • Modified release capsules
  • Modified release tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
Important
Modified-release preparations to be prescribed by brand
04.07.04
04.08.01
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
Capsules (Sprinkle) reserved for use in patients who cannot swallow tablets.
04.07.04
04.08.01
Green (see narrative)
Formulations :
  • Oral suspension
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
Only use where patient cannot swallow tablets or capsules (sprinkle) are not suitable.
07.04.02
Green (see narrative)
Formulations :
  • Oral suspension
Primary Care
ASPH
RSCH
SASH
SABP
Important
Only for patients with swallowing difficulties. Prescribe as solifenacin 1mg/ml oral SUSPENSION
Green (see narrative)
Formulations :
  • Modified release tablets
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
2nd or 3rd line. Tamsulosin MR capsules or Doxazosin immediate release tablets are preferred
Green (see narrative)
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
R
Important
Restricted for patients with renal or hepatic failure
01.03.05
Blue
Formulations :
  • Oral suspension
Primary Care
ASPH
RSCH
SASH
SABP
Blue
Formulations :
  • Modified release tablets
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
R
Important
Only on recommendation by a pain specialist for patients not responding to / not tolerating morphine or oxycodone
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
01.03.05
Blue
Formulations :
  • Oral suspension
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
R
Important
Only for children under 10kg and/or with a feeding tube less than 8Fr
04.09.01
Blue
Formulations :
  • Capsules
  • Capsules (slow release)
  • Dispersible tablets
Primary Care
ASPH
RSCH
SASH
SABP
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
04.09.01
Blue
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSCH
SASH
SABP
04.09.01
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
04.09.01
Blue
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSCH
SASH
SABP
04.09.01
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
Preferred
Preferred COMT inhibitor
04.09.01
Blue
Formulations :
  • Patches
Primary Care
ASPH
RSCH
SASH
SABP
Important
Consider patches if levodopa and / or oral dopamine are not effective in treating nocturnal akinesia
01.05.02
06.03.02
Blue
Formulations :
  • Oro-dispersible
Primary Care
ASPH
RSCH
SASH
SABP
04.08.01
10.02.02
Blue
Formulations :
  • Oromucosal spray
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
Important
For spasticity in MS. Specialist to prescribe for the first 12 weeks and determine response before transfer of care.
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Blue
Formulations :
  • Eye drops (unit dose)
Primary Care
ASPH
RSCH
SASH
SABP
Important
0.1% ciclosporin (Ikervis)
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
04.08.01
04.08.02
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
Un
Important
Rapid eye movement disorder
04.01.01
Blue
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
Un
Important
Rapid eye movement disorder.
Generic 2mg MR tablets.
Blue
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
Blue
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
06.01.02
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
04.02.01
Blue
Formulations :
  • Modified release tablets
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
Un
06.01.02
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
06.04.02
Amber
Formulations :
  • Gel
  • Injection
Primary Care
ASPH
RSCH
SASH
SABP
06.07.02
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSCH
SASH
SABP
Amber
Formulations :
  • Implant
Primary Care
ASPH
RSCH
SASH
SABP
06.07.02
08.03.04
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSCH
SASH
SABP
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
06.04.01
07.02.01
Amber
Formulations :
  • Gel
  • Patches
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
06.04.01
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
06.04.02
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
10.01.03
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
Un
10.01.03
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
Un
Amber
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.08.01
Amber
Formulations :
  • Gastro-resistant tablets
  • Modified release tablets
  • Oral solution
  • Tablets
  • Crushable tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.08.01
Red
Formulations :
  • Injection
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.07.02
Red
Formulations :
  • Injection
  • Solution for infusion
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
04.07.02
Red
Formulations :
  • Injection
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
CD
Important
2nd-line, for patients unable to tolerate / poor response to morphine. Modified-release preparations to be prescribed by brand
04.07.04
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSCH
SASH
SABP
Preferred
04.07.04
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSCH
SASH
SABP
06.07.01
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
SA
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
04.09.01
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
01.03.05
Red
Formulations :
  • Powder
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
R
U
Important
Aclomep powder - ASPH NICU only
04.02.01
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
Important
Patient monitoring and registration required
04.06.00
Red
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
SA
Important
Safety alert and cardiac side-effects. Max treatment duration of 1 week
Red
Formulations :
  • Capsules
Primary Care
ASPH
RSCH
SASH
SABP
11.04.01
Red
Formulations :
  • Intravitreal implant
Primary Care
ASPH
RSCH
SASH
SABP
Important
Ophthalmology specialists only
Red
Formulations :
  • Eye drops
Primary Care
ASPH
RSCH
SASH
SABP
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NHSE
01.03.03
Red
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
U
01.05.03
10.01.03
13.05.02
13.05.03
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSCH
SASH
SABP
10.01.03
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSCH
SASH
SABP
10.01.03
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSCH
SASH
SABP
Important
Severe disease only
01.05.03
10.01.03
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
Severe disease only
13.05.03
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSCH
SASH
SABP
01.05.03
10.01.03
13.05.03
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
10.01.03
13.05.03
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
01.05.03
10.01.03
13.05.02
13.05.03
Red
Formulations :
  • Intravenous injection (IV)
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSCH
SASH
SABP
Red
Formulations :
  • Device
Primary Care
ASPH
RSCH
SASH
SABP
09.06.04
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
25,000iu tablets
04.07.04
Red
Formulations :
  • Oral lyophilisates
Primary Care
ASPH
RSCH
SASH
SABP
Important
For episodic migraine only
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
13.05.02
13.05.03
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
Red
Formulations :
  • Capsules
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
R
Un
Important
Consultant psychiatrists only.
04.06.00
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
Un
04.08.01
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
Important
For initiation by tertiary centres only
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
06.01.02
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSCH
SASH
SABP
04.06.00
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
SA
Un
N/A
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
06.01.02
N/A
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSCH
SASH
SABP
N/A
Formulations :
  • Device
Primary Care
ASPH
RSCH
SASH
SABP
06.04.02
Non Formulary
Formulations :
  • Cream
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
U
Important
Androfeme is unlicensed in the UK. Other products can be used off-label
Non Formulary
Formulations :
  • Ointment
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
U
Important
0.4% ointment is the 1st-line treatment option in adults. 0.1%, 0.2% and 2% ointments are non-formulary
01.05.02
Non Formulary
Formulations :
  • Foam enema
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Important
Budesonide rectal foam is preferred. Steroid safety considerations
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Un
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSCH
SASH
SABP
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSCH
SASH
SABP
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSCH
SASH
SABP
04.07.03
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
04.01.01
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
04.02.01
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
01.03.05
Non Formulary
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
01.03.05
Non Formulary
Formulations :
  • Liquid
  • Oral solution
  • Oral suspension
Primary Care
ASPH
RSCH
SASH
SABP
Important
Lansoprazole oro-dispersible tablets are 1st-line for adults with swallowing dificulties or enteral feeding tubes.
01.03.05
Non Formulary
Formulations :
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Important
Omeprazole or lansoprazole capsules are 1st-line. Pantoprazole or rabeprazole tablets are 2nd-line for patients without swallowing difficulties (suitable for patients that cannot have animal-derived products).
01.03.05
Non Formulary
Formulations :
  • Oral suspension
  • Oro-dispersible
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Important
Omeprasole capsules can be opened for patients with swallowig difficulties. Lansoprazole oro-dispersible tablets are 1st-line for patients with enteral feeding tubes
04.09.01
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
04.09.01
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
04.09.01
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
04.09.01
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
04.07.03
04.07.04
04.08.01
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
04.07.03
04.07.04
04.08.01
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
07.04.02
Non Formulary
Formulations :
  • Oral solution
Primary Care
ASPH
RSCH
SASH
SABP
Important
Prescribe as solifenacin 1mg/ml oral SUSPENSION
Non Formulary
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Important
Use modified release capsules
07.04.01
Non Formulary
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Important
Use immediate release tablets
07.04.01
07.04.05
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
07.04.01
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
07.04.01
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
07.04.01
07.04.05
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
04.07.03
07.04.02
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSCH
SASH
SABP
10.03.02
Non Formulary
Formulations :
  • Patches
Primary Care
ASPH
RSCH
SASH
SABP
BNF SPC
NFD1
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
06.04.02
See narrative
Formulations :
  • Gel
  • Injection
Primary Care
ASPH
RSCH
SASH
SABP
06.07.02
See narrative
Formulations :
  • Injection
Primary Care
ASPH
RSCH
SASH
SABP
06.04.01
07.02.01
See narrative
Formulations :
  • Patches
  • Tablets
Primary Care
ASPH
RSCH
SASH
SABP
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More